Dose-response relationships for human tumors: implications for clinical trials of dose modifying agents.
Clinical benefit from dose modifying agents depends upon the effectiveness of the agents and the steepness of dose response curves for the local control of human tumors by radiotherapy. We have analyzed the two prospective trials and the many retrospective analyses of clinical data from the literature to determine what dose increment is needed to increase local control from 40 to 60%. This increment ranges from 3 to greater than 35%. Thus a dose modifying factor of at least 1.03 (to greater than 1.35) will be necessary for clinical detection of the benefit of a new modality, even if 135 patients are included in each arm of a trial. Two dose levels in the new treatment arm would ensure that therapeutic advantage could be assessed, and would also generate prospective dose response information.
D000818:Animals; D002986:Clinical Trials as Topic; D004307:Dose-Response Relationship, Radiation; D017341:Etanidazole; D006801:Humans; D051379:Mice; D008920:Misonidazole / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D017341:Etanidazole; C033815:pimonidazole; D008920:Misonidazole